Concepedia

Natasha Reddinger

NR

Statistics

Publications

3

Citations

110

H-Index

3

Active since

2011

Affiliations

Sarah Cannon(Current)

Natasha Reddinger is an author at Sarah Cannon specializing in medicine, pharmacology, and tyrosine kinase inhibitors.

Publications per year

2011–2020

3

Publications

3

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

Michael Millward, Paul N. Mainwaring, Alain C. Mita et al. · Investigational New Drugs · 2011 · 74 citations

, , +5

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

Alexander Drilon, Filippo de Braud, Salvatore Siena et al. · Cancer Research · 2016 · 23 citations

, , +16

Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).

Ivor Percent, Craig H. Reynolds, Kartik Konduri et al. · Journal of Clinical Oncology · 2020 · 13 citations

, , +17

1–3 of 3